These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24498905)

  • 1. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.
    Li CJ; Yu Q; Yu P; Yu TL; Zhang QM; Lu S; Yu DM
    Cardiovasc Diabetol; 2014 Feb; 13():36. PubMed ID: 24498905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
    Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
    Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
    Lovshin JA; Barnie A; DeAlmeida A; Logan A; Zinman B; Drucker DJ
    Diabetes Care; 2015 Jan; 38(1):132-9. PubMed ID: 25414155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
    Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
    Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
    Feng WH; Bi Y; Li P; Yin TT; Gao CX; Shen SM; Gao LJ; Yang DH; Zhu DL
    J Diabetes Investig; 2019 Mar; 10(2):399-407. PubMed ID: 29957886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
    Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals.
    Cheng S; Fox CS; Larson MG; Massaro JM; McCabe EL; Khan AM; Levy D; Hoffmann U; O'Donnell CJ; Miller KK; Newton-Cheh C; Coviello AD; Bhasin S; Vasan RS; Wang TJ
    Am J Cardiol; 2011 Oct; 108(7):979-84. PubMed ID: 21813106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
    Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
    J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
    Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ
    PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
    Feng P; Yu DM; Chen LM; Chang BC; Ji QD; Li SY; Zhu M; Ding SH; Zhang BZ; Wang SL; Li HT; Lin JN; Wang MJ; Guo JC; Liu J; Liu ZD; Wu ST; Yang JH
    Acta Pharmacol Sin; 2015 Feb; 36(2):200-8. PubMed ID: 25619391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.
    Inoue K; Maeda N; Kashine S; Fujishima Y; Kozawa J; Hiuge-Shimizu A; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2011 Dec; 10():109. PubMed ID: 22132774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease.
    Osajima A; Okazaki M; Kato H; Anai H; Tsuda Y; Segawa K; Tanaka H; Tamura M; Takasugi M; Nakashima Y
    Am J Nephrol; 2001; 21(2):112-9. PubMed ID: 11359018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natriuretic peptides as markers of preclinical cardiac disease in obesity.
    Grandi AM; Laurita E; Selva E; Piantanida E; Imperiale D; Giovanella L; Guasti L; Venco A
    Eur J Clin Invest; 2004 May; 34(5):342-8. PubMed ID: 15147331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
    Perna S; Guido D; Bologna C; Solerte SB; Guerriero F; Isu A; Rondanelli M
    Aging Clin Exp Res; 2016 Dec; 28(6):1251-1257. PubMed ID: 26749118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
    de Luis DA; Ovalle HF; Soto GD; Izaola O; de la Fuente B; Romero E
    J Investig Med; 2014 Feb; 62(2):324-7. PubMed ID: 24322329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.
    Raun K; von Voss P; Gotfredsen CF; Golozoubova V; Rolin B; Knudsen LB
    Diabetes; 2007 Jan; 56(1):8-15. PubMed ID: 17192459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.
    Nousiainen T; Vanninen E; Jantunen E; Puustinen J; Remes J; Rantala A; Vuolteenaho O; Hartikainen J
    J Intern Med; 2002 Mar; 251(3):228-34. PubMed ID: 11886482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.
    Yagi K; Imamura T; Tada H; Chujo D; Liu J; Shima Y; Ohbatake A; Miyamoto Y; Okazaki S; Ito N; Nakano K; Shikata M; Enkaku A; Takikawa A; Honoki H; Fujisaka S; Origasa H; Tobe K
    J Diabetes Res; 2021; 2021():8838026. PubMed ID: 33855087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.
    Okada K; Kotani K; Yagyu H; Ando A; Osuga J; Ishibashi S
    Endocrine; 2014 Dec; 47(3):962-4. PubMed ID: 24696097
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.